Beijing Wantai Biological Pharmacy Enterprise Past Earnings Performance
Past criteria checks 0/6
Beijing Wantai Biological Pharmacy Enterprise has been growing earnings at an average annual rate of 17.2%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 21.7% per year.
Key information
17.2%
Earnings growth rate
16.4%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 21.7% |
| Return on equity | -2.3% |
| Net Margin | -11.8% |
| Next Earnings Update | 12 Apr 2025 |
Recent past performance updates
Recent updates
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) Analysts Are Reducing Their Forecasts For This Year
Jul 26
These 4 Measures Indicate That Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Is Using Debt Reasonably Well
Jul 22Some Investors May Be Willing To Look Past Beijing Wantai Biological Pharmacy Enterprise's (SHSE:603392) Soft Earnings
Apr 04Things Look Grim For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) After Today's Downgrade
Apr 02Earnings Tell The Story For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) As Its Stock Soars 27%
Feb 28Revenue & Expenses Breakdown
How Beijing Wantai Biological Pharmacy Enterprise makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,490 | -294 | 914 | 1,090 |
| 30 Jun 24 | 2,713 | -194 | 995 | 1,188 |
| 31 Mar 24 | 3,377 | 128 | 1,214 | 1,165 |
| 31 Dec 23 | 5,511 | 1,248 | 1,936 | 1,177 |
| 30 Sep 23 | 7,504 | 2,600 | 2,541 | 1,524 |
| 30 Jun 23 | 9,419 | 3,745 | 3,197 | 1,318 |
| 31 Mar 23 | 10,901 | 4,650 | 3,509 | 1,203 |
| 31 Dec 22 | 11,185 | 4,736 | 3,581 | 1,091 |
| 30 Sep 22 | 10,805 | 4,777 | 3,455 | 604 |
| 30 Jun 22 | 9,716 | 3,993 | 3,123 | 708 |
| 31 Mar 22 | 8,098 | 3,063 | 2,779 | 705 |
| 31 Dec 21 | 5,750 | 2,021 | 1,958 | 677 |
| 30 Sep 21 | 4,351 | 1,398 | 1,554 | 570 |
| 30 Jun 21 | 3,475 | 1,155 | 1,232 | 382 |
| 31 Mar 21 | 2,867 | 896 | 1,011 | 343 |
| 31 Dec 20 | 2,354 | 677 | 834 | 309 |
| 30 Sep 20 | 1,953 | 551 | 704 | 243 |
| 30 Jun 20 | 1,504 | 368 | 552 | 223 |
| 31 Mar 20 | 1,244 | 239 | 516 | 178 |
| 31 Dec 19 | 1,184 | 209 | 511 | 164 |
| 30 Sep 19 | 1,096 | 217 | 472 | 149 |
| 30 Jun 19 | 1,054 | 269 | 455 | 141 |
| 31 Mar 19 | 1,007 | 279 | 428 | 134 |
| 31 Dec 18 | 983 | 293 | 421 | 137 |
| 31 Dec 17 | 950 | 150 | 362 | 158 |
| 31 Dec 16 | 844 | 148 | 350 | 128 |
| 31 Dec 15 | 681 | 119 | 269 | 109 |
| 31 Dec 14 | 596 | 118 | 322 | 0 |
Quality Earnings: 603392 is currently unprofitable.
Growing Profit Margin: 603392 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603392 is unprofitable, but has reduced losses over the past 5 years at a rate of 17.2% per year.
Accelerating Growth: Unable to compare 603392's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 603392 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).
Return on Equity
High ROE: 603392 has a negative Return on Equity (-2.34%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 10:24 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Zhizhong Jing | China Merchants Securities Co. Ltd. |
| Wei Sun | China Merchants Securities Co. Ltd. |